89bio rises on FDA's 'breakthrough therapy' for NASH treatment
21/09/2023 16:24
** Shares of drug developer 89bio Inc rise 1.69% to $15.32
** Co says US FDA has granted "breakthrough therapy" tag to
lead drug pegozafermin in patients with a liver disease called
nonalcoholic steatohepatitis (NASH)
** Discussions with regulatory agencies regarding the
late-stage trials planned for Q4 2023
** NASH is a fatty liver disease where fat accumulation and
inflammation can lead to scarring, or fibrosis, that impairs
liver function
** "Breakthrough therapy" tag is meant to speed up the
development and review of drugs to treat a serious condition or
unmet medical need
** Stock up ~21% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))